{"entity":{"id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TQB2102 and TQB2930 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","summary":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07512583 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 178 participants planned, started 2026-05-27 and due to reach its primary completion in 2028-03. Interventions recorded: TQB2930 injection+TQB2102 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07512583","url":"https://clinicaltrials.gov/study/NCT07512583"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb2102","tqb2930"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07512583","phase":"1/2","setting":"Phase Ib/II Clinical Trial of TQB2930 Injection in Combination With TQB2102 for Injection in Patients With HER2-Expressing Advanced Solid Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","enrolled":178,"outcomes":[]},"route":"/trials/nct07512583/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"},{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}